Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies.
Medicine February 28, 2025 Yannan Ouyang, Juan Li 8 citations
A systematic review and meta-analysis of five randomized controlled trials found that esketamine nasal spray, compared to a control treatment, significantly reduced depression severity measured by the MADRS scale, increased the rate of response, and improved functioning and depressive symptoms on the Sheehan Disability Scale and PHQ-9. However, it also led to more dizziness and nausea. The results suggest esketamine nasal spray is beneficial for treatment-resistant depression.